IP4 fundamentals
An in-depth look to INNOCAN PHARMA CORP. operating, investing, and financing activities
IP4 free cash flow for Q1 24 is -691.06 k EUR. For 2023, IP4 free cash flow was -3.64 M EUR and operating cash flow was -3.6 M EUR.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM